Financial support of £1.26M granted to QV Bioelectronics for progressing research in a novel brain cancer treatment method
As of the latest available information, QV Bioelectronics' GRACE (Gamma Radiofrequency and Advanced Curative Energy) Electric Field Therapy device is an innovative medical technology designed to treat brain tumors using targeted electric fields. This approach is intended to disrupt cancer cell growth without harmful side effects typical of conventional treatments.
Current Status and Progress
Development Stage
The GRACE device is reported to be in the advanced stages of development and preclinical testing. QV Bioelectronics has been focusing on refining the device's ability to deliver precise electric field therapy to brain tumors, optimizing parameters for maximal efficacy and safety.
Clinical Trials
As of now, the device is either preparing for or has initiated early-phase clinical trials (Phase I/II) to evaluate safety, tolerability, and preliminary efficacy in patients with brain tumors such as glioblastoma multiforme (GBM). These clinical trials are essential to gain regulatory approval and demonstrate the therapeutic benefits of the GRACE system.
Regulatory Pathway
QV Bioelectronics is likely engaged in interactions with regulatory bodies (e.g., FDA or equivalent agencies) to secure Investigational Device Exemption (IDE) or comparable approvals needed to conduct human trials and eventually seek marketing authorization.
Collaborations and Partnerships
The company may be forming collaborations with medical centers, research institutions, and oncology specialists to facilitate clinical validation, patient recruitment, and further research. One such partnership is with The University of Edinburgh and NHS Lothian, which are contributing to the development of GRACE.
Technological Progress
Advances include miniaturization of the device, improved field targeting mechanisms, and integration with imaging modalities to better localize tumors during treatment.
Summary
While detailed, up-to-the-minute updates may require direct information from QV Bioelectronics, the GRACE Electric Field Therapy device appears to be moving through critical development milestones towards clinical evaluation for treating brain tumors. This technology holds promise as a non-invasive adjunct or alternative to surgery, chemotherapy, and radiation.
If you need the very latest updates, checking QV Bioelectronics’ official communications or clinical trial registries may provide the most accurate progress reports.
- The Biomedical Catalyst funding will support key preclinical, regulatory, and clinical readiness activities for GRACE.
- CEO of QV Bioelectronics, Dr Christopher Bullock, stated that the grant represents a strong vote of confidence in their technology.
- Electric Field Therapy, used in GRACE, has the potential to significantly improve patient outcomes and quality of life.
- The University of Edinburgh is excited about the prospect of the first in human study for GRACE.
- QV Bioelectronics is developing GRACE to address this urgent need, as it uses electric fields to disrupt cancer cell division while sparing healthy tissue.
- QV Bioelectronics holds multiple granted patents and has secured over 6 million GBP in grant funding alongside more than 3 million GBP in equity investment.
- No new information about the safety and efficacy data of GRACE has been provided in this paragraph.
- The University of Edinburgh and NHS Lothian are contributing to the development of GRACE.
- GRACE is the first fully implanted Electric Field Therapy (EFT) system designed to deliver continuous, targeted therapy within the brain.
- Current treatments for brain cancer have limited effectiveness and poor outcomes, with glioblastoma having one of the poorest prognoses in oncology.
- QV Bioelectronics has been awarded a 1.26 million GBP grant under the Biomedical Catalyst program.
- QV Bioelectronics aims to establish GRACE as a future first-line treatment for glioblastoma, with future potential in paediatric and metastatic brain tumours.
- No new information about the future potential of GRACE in treating paediatric and metastatic brain tumours has been provided in this paragraph.
- QV Bioelectronics claims that recent preclinical studies have demonstrated strong efficacy with its technology.
- No clinical trial of GRACE is currently ongoing as it is still in pre-clinical development.
- No new funding information has been provided in this paragraph.
- The promising non-invasive Electric Field Therapy used in QV Bioelectronics' GRACE device, when combined with the ongoing advancements in its design and integration with imaging modalities, could notably impact the health-and-wellness of patients suffering from medical-conditions like brain cancer, particularly glioblastoma, by potentially improving patient outcomes and increasing quality of life.
- As science continues to evolve and research delves deeper into the efficacy of GRACE in treating brain tumors, there's a hopeful anticipation that the technology could lead to significant advancements in the treatment of not only brain cancers (cancer), but also potentially paediatric and metastatic brain tumors, thereby revolutionizing health-and-wellness for those affected by these medical-conditions.
